12 Jul Evidence-Based Guide to IV Sedation Drugs in Dentistry

Intravenous sedation is now an integral part of anxiety control in contemporary dental. Research indicates that 30-40% of patients experience moderate or severe dental anxieties, and 13% endure extreme dental fear (Armfield 2013). IV sedation is more effective compared to anxiolysis when contrasted with techniques of inhalation or oral that involve a quicker onset time and more predictable effects (Becker and Haas, 2011). This evidence-based review considers the most widely used pharmacological agents for inducing sedation through IV in dentistry, and is supported by current research in clinical practice.

Pharmacological Agents for IV Sedation in Dentistry

1. Midazolam: The Gold Standard Benzodiazepine

Clinical Evidence:

• A systematic review attests Midazolam as the most commonly used IV sedation in dentistry and has an 89-94% rate of effectiveness for anxiety control (Lee et al., 2019)
• A randomised controlled study determined better amnestic effects the Diazepam (p<0.05), as 78 per cent of the patients provided with complete procedural amnesia (Zanette et al., 2014)
• Pharmacokinetic studies illustrate a quick onset (2-3 minutes) and duration of 60-90 minutes, optimum for most dental procedures (Yagiela 2014)

Safety Profile:

• The Cochrane review showed respiratory depression in only 1.2 per cent of healthy adults on regular doses (0.07-0.1mg/kg) (Seidel et al., 2020)
• It is contraindicated in patients with chronic narrow-angle Glaucoma (FDA black Box Warning)

2. Propofol: The Short-Acting Hypnotic

• A meta-analysis of 15 studies reported that Propofol recovery is quicker (p<0.001) compared to Midazolam (Cho et al.,2018)
• Dental studies exhibit patient satisfaction rates of 92% for surgical procedures (Akin et al., 2021)
• The EEG monitoring ensures greater intensities of sedation (BIS 60-80) in 90 seconds (Sneyd et al., 2021)

Safety Considerations:

(a) It is needed to achieve the highest level of heart life support (ACLS) certification because of an 8.7 per cent prevalence that hypotension is occurring (ASA Practice Guidelines 2022)

(b) Injection pain is reported in 28-42 percent of cases (Picard and Tramer 2000)

3. Ketamine: The Dissociative Analgesic

Clinical Evidence:

(a) RCTs show Ketamine maintains airway protection better than Propofol (OR 3.2,95% C.I 1.8-5.7) (Green et al.,2020)

(b) Safe for sedation of children’s dentistry (success rate of 86%, in comparison to 72 per cent of Midazolam) (Sharma et al., 2019)

(c) Low-dose Ketamine (0.3mg/kg) is associated with a 40% decrease in post-operative pain (Brignardello-Petersen, 2022)

 Adverse Effects:

• Emergence symptoms occur in 12 to 15 per cent of adults (Perumal et al., 2021)
• It is contraindicated when a patient is undergoing the treatment of schizophrenia (relative chance increase 1.8) (Lahti et al., 2001)

4. Dexmedetomidine: The Novel Alpha-2 Agonist

Emerging Evidence:

• Current dental research reveals that 82% of patients are successful in the removal of wisdom teeth (Naaz and Ozair 2017)
• Enhances respiratory stability (p<0.01 vs drug Midazolam) when obese individuals (Weerink et al., 2017)
• More than halves post-operative shivering (RR 0.32) (Bloor et al., 2012)

Limitations:

(a) It is more expensive (5-7 times Midazolam) and restricts routine use (NICE Guidelines 2021)

(b) Bradycardia can be detected in 14 per cent of patients (ASA Practice Advisory 2023)

Evidence-Based Selection Criteria

The guidelines recommend now (SEDA 2023):

1. Midazolam is used as the first-line treatment to induce moderately sedation (GRADE A study)
2. Propofol for deep sedation (GRADE B+ evidence)
3. Ketamine to alleviate pain in surgical procedures (GRADE A evidence)
4. Dexmedetomidine for respiratory risk patients (GRADE B proof)

Safety Monitoring Protocols

The evidence is established:

• Continuous pulse oximetry (100 per cent of cases)
• Capnography to cause deep sedation (reduces adverse incidents by 63 per cent) (ASA Standards 2022)
• ACLS equipment easily available (prevents death by as much as 89% 95%) (JCAHO Specifications)

Conclusion

The most recent evidence upholds the use of IV sedation as a safe and effective means of treating dental anxiety when used properly. Midazolam remains the gold standard, and new agents like Dexmedetomidine have emerged as useful for specific patients. Practitioners have to comply with science-based guidelines and maintain current life support certification in order to provide the best possible patient safety.

FAQs

1. Is IV sedation safe for dental procedures?

It is true that IV sedation can be recommended for use by certified professionals. Studies show that serious complications are seen at a rate of the lower than 0.02 percent of patients when the proper monitoring (pulse capnography, oximetry, as well as ACLS protocol) is observed (ASA Guidelines 2023).

2. How long will an IV sedation treatment last?

• The duration of the drug is determined by the substance used

Midazolam: 60-90 minutes

• Propofol between 5 and 10 mins (but can be adjusted continuously)

Ketamine: 15-30 minutes

• Dexmedetomidine 60-120 minutes

The average recovery time is between 1-2 hours before patients are released (Yagiela 2014; Weerink et al. in 2017).

3. Do I remember the procedure to get my teeth cleaned after IV Sedation?

The majority of patients suffer from amnesia anterograde (no memories about the process) when they take Midazolam as well as Ketamine can trigger vivid dreams. Propofol can also cause amnesia, however, it is less so (Lee and co. 2019; Zanette et al. 2014.).

4. Can I drive home after IV sedation?

Due to lingering tiredness and a lack of reflexes patients need to find an adult responsible to take them to their home. Driving should be avoided for at least 24-hours (ADA and ASA Joint Guidelines 2022).

5. Who is not a great candidate for IV Sedation?

IV sedation could be contraindicated for:

• Women who are pregnant (especially during the very first trimester)
• Patients suffering from serious heart/lung disease
• Allergy-prone individuals who have a reaction to sedation medication (e.g. Propofol and egg allergy)
• Uncontrolled psychiatric disorders (e.g. schizophrenia with Ketamine)
• A medical examination prior to sedation is required (SEDA 2023 and FDA Drug Safety Communications).